Werewolf Therapeutics, Inc.
HOWL
$0.38
$0.00-0.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 21.00M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.00M | -- | -- | -- | -- |
| Cost of Revenue | 4.64M | 4.50M | 6.18M | 10.86M | 12.37M |
| Gross Profit | 16.36M | -4.50M | -6.18M | -10.86M | -12.37M |
| SG&A Expenses | 7.82M | 4.47M | 3.24M | 4.86M | 5.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.46M | 8.97M | 9.42M | 15.73M | 17.54M |
| Operating Income | 8.54M | -8.97M | -9.42M | -15.73M | -17.54M |
| Income Before Tax | 3.67M | -13.53M | -8.38M | -16.37M | -17.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.67M | -13.53M | -8.38M | -16.37M | -17.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.67M | -13.53M | -8.38M | -16.37M | -17.98M |
| EBIT | 8.54M | -8.97M | -9.42M | -15.73M | -17.54M |
| EBITDA | 10.99M | -8.57M | -9.02M | -15.32M | -17.14M |
| EPS Basic | 0.08 | -0.28 | -0.17 | -0.36 | -0.40 |
| Normalized Basic EPS | 0.11 | -0.12 | -0.11 | -0.22 | -0.25 |
| EPS Diluted | 0.08 | -0.28 | -0.20 | -0.36 | -0.40 |
| Normalized Diluted EPS | 0.11 | -0.12 | -0.11 | -0.22 | -0.25 |
| Average Basic Shares Outstanding | 48.60M | 48.60M | 48.43M | 45.80M | 44.98M |
| Average Diluted Shares Outstanding | 48.60M | 48.60M | 49.22M | 45.80M | 44.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |